Viekirax Tablets / Film-coated
Ombitasvir, Paritaprevir (ABT-450), Ritonavir (Function as PK enhancer)
"12.5mg, 75mg, 50mg"
ABBVIE DEUTSCHLAND GmbH & CO. KG
| Pack size | 56's (14's pack x 4) |
|---|---|
| Dispensing mode | POM |
| Source | GERMANY |
| Agent | CITY MEDICAL STORE |
| Retail Price | 88950.00 AED |
Indications
Viekirax Tablets / Film-coated is used for:
OMBITASVIR
When used within the fixed dose combination product of paritaprevir/ombitasvir/ritonavir (technivie), ombitasvir is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis c virus (hcv) infection without cirrhosis. When used within the fixed dose combination product of paritaprevir/ombitasvir/dasabuvir/ritonavir (viekira pak), ombitasvir is indicated for the treatment of hcv genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with ribavirin for the treatment of hcv genotype 1a without cirrhosis or with compensated cirrhosis
PARITAPREVIR
When used within the fixed dose combination product of paritaprevir/ombitasvir/ritonavir (technivie), paritaprevir is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis c virus (hcv) infection without cirrhosis. When used within the fixed dose combination product of paritaprevir/ombitasvir/dasabuvir/ritonavir (viekiera pak), paritaprevir is indicated for the treatment of hcv genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with ribavirin for the treatment of hcv genotype 1a without cirrhosis or with compensated cirrhosis
RITONAVIR
Indicated in combination with other antiretroviral agents for the treatment of hiv-infection
When used within the fixed dose combination product of paritaprevir/ombitasvir/ritonavir (technivie), ombitasvir is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis c virus (hcv) infection without cirrhosis. When used within the fixed dose combination product of paritaprevir/ombitasvir/dasabuvir/ritonavir (viekira pak), ombitasvir is indicated for the treatment of hcv genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with ribavirin for the treatment of hcv genotype 1a without cirrhosis or with compensated cirrhosis
PARITAPREVIR
When used within the fixed dose combination product of paritaprevir/ombitasvir/ritonavir (technivie), paritaprevir is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis c virus (hcv) infection without cirrhosis. When used within the fixed dose combination product of paritaprevir/ombitasvir/dasabuvir/ritonavir (viekiera pak), paritaprevir is indicated for the treatment of hcv genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with ribavirin for the treatment of hcv genotype 1a without cirrhosis or with compensated cirrhosis
RITONAVIR
Indicated in combination with other antiretroviral agents for the treatment of hiv-infection
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Ombitasvir, Paritaprevir (ABT-450), Ritonavir (Function as PK enhancer) :
Mechanism of Action
OMBITASVIR
Ombitasvir is a direct acting inhibitor of nonstructural protein 5a (ns5a) of hepatitis c virus (hcv). Despite lacking enzymatic activity, ns5a is necessary for viral replication and virion assembly through interaction with other nonstructural proteins
PARITAPREVIR
Paritaprevir is a potent inhibitor of the ns3/4a serine protease of hepatitis c virus (hcv). Following viral replication of hcv genetic material and translation into a single polypeptide, nonstructural protein 3 (ns3) and its activating cofactor nonstructural protein 4a (ns4a) are responsible for cleaving it into the following structural and nonstructural proteins required for assembly into mature virus: ns3, ns4a, ns4b, ns5a, and ns5b. By inhibiting viral protease ns3/4a, paritaprevir therefore prevents viral replication and function
RITONAVIR
Ritonavir inhibits the hiv viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles
Ombitasvir is a direct acting inhibitor of nonstructural protein 5a (ns5a) of hepatitis c virus (hcv). Despite lacking enzymatic activity, ns5a is necessary for viral replication and virion assembly through interaction with other nonstructural proteins
PARITAPREVIR
Paritaprevir is a potent inhibitor of the ns3/4a serine protease of hepatitis c virus (hcv). Following viral replication of hcv genetic material and translation into a single polypeptide, nonstructural protein 3 (ns3) and its activating cofactor nonstructural protein 4a (ns4a) are responsible for cleaving it into the following structural and nonstructural proteins required for assembly into mature virus: ns3, ns4a, ns4b, ns5a, and ns5b. By inhibiting viral protease ns3/4a, paritaprevir therefore prevents viral replication and function
RITONAVIR
Ritonavir inhibits the hiv viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles
Note
Viekirax "12.5mg, 75mg, 50mg" Tablets / Film-coated manufactured by ABBVIE DEUTSCHLAND GmbH & CO. KG. Its generic name is Ombitasvir, Paritaprevir (ABT-450), Ritonavir (Function as PK enhancer). Viekirax is availble in United Arab Emirates.
Farmaco UAE drug index information on Viekirax Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.